Literature DB >> 8719105

Human lymphocytes are more susceptible to measles virus than granulocytes, which is attributable to the phenotypic differences of their membrane cofactor protein (CD46).

M Kurita1, Y Yanagi, T Hara, S Nagasawa, M Matsumoto, T Seya.   

Abstract

Membrane cofactor protein (MCP, CD46) of the complement system is a measles virus (MV) receptor. Human lymphocytes express a heavily glycosylated (H) and a lightly glycosylated (L) form of MCP, which confers a two-band profile on SDS-PAGE the ratio of which is controlled genetically and organ-specifically. In contrast, granulocytes express a single heavily glycosylated form regardless of lymphocyte MCP phenotype. We investigated susceptibility to MV of granulocytes and lymphocytes from individuals with different lymphocyte MCP phenotypes. In any individual, granulocytes were > 10-fold less susceptible to MV than lymphocytes, and the lymphocytes with predominant H form were generally less susceptible to those with an increasing amount of L form. Thus, lymphocytes always exhibit high susceptibility to MV compared to granulocytes in all individuals. This finding may explain the lymphopenia and immunosuppression observed secondary to MV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719105     DOI: 10.1016/0165-2478(95)02447-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  Molecular and functional analysis of mouse decay accelerating factor (CD55).

Authors:  C L Harris; N K Rushmere; B P Morgan
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

2.  Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia.

Authors:  Patrick L Sinn; Greg Williams; Sompong Vongpunsawad; Roberto Cattaneo; Paul B McCray
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 3.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.